Immunotherapy with myeloid cells for tolerance induction.

PubWeight™: 0.78‹?›

🔗 View Article (PMC 3718485)

Published in Curr Opin Organ Transplant on August 01, 2010

Authors

Mercedes Rodriguez-García1, Peter Boros, Jonathan S Bromberg, Jordi C Ochando

Author Affiliations

1: Immunología de Trasplantes, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain.

Articles cited by this

Taking dendritic cells into medicine. Nature (2007) 11.82

Differential antigen processing by dendritic cell subsets in vivo. Science (2007) 8.42

Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med (2000) 6.45

Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol (2006) 5.00

Immunologic 'ignorance' of vascularized organ transplants in the absence of secondary lymphoid tissue. Nat Med (2000) 3.25

Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med (2007) 3.22

Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol (2010) 3.18

Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. J Exp Med (2009) 3.13

Migration of dendritic cell subsets and their precursors. Annu Rev Immunol (2008) 3.04

Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol (1999) 2.94

Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol (2001) 2.75

CD8+ CD205+ splenic dendritic cells are specialized to induce Foxp3+ regulatory T cells. J Immunol (2008) 2.69

Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol (2007) 2.61

Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival. Am J Transplant (2005) 2.32

Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur J Immunol (2000) 2.24

Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc Natl Acad Sci U S A (2009) 2.22

1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol (2009) 2.22

Tuning microenvironments: induction of regulatory T cells by dendritic cells. Immunity (2008) 2.09

Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation (1996) 1.86

Evidence for recruitment of plasmacytoid dendritic cell precursors to inflamed lymph nodes through high endothelial venules. Int Immunol (2004) 1.85

Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1. Eur J Immunol (2009) 1.76

Development and function of myeloid-derived suppressor cells generated from mouse embryonic and hematopoietic stem cells. Stem Cells (2010) 1.75

Topically applied 1,25-dihydroxyvitamin D3 enhances the suppressive activity of CD4+CD25+ cells in the draining lymph nodes. J Immunol (2007) 1.74

Dominant role of antigen dose in CD4+Foxp3+ regulatory T cell induction and expansion. J Immunol (2009) 1.59

Activation of the aryl hydrocarbon receptor promotes allograft-specific tolerance through direct and dendritic cell-mediated effects on regulatory T cells. Blood (2008) 1.58

Monocytic suppressive cells mediate cardiovascular transplantation tolerance in mice. J Clin Invest (2010) 1.55

Tumor necrosis factor-dependent segmental control of MIG expression by high endothelial venules in inflamed lymph nodes regulates monocyte recruitment. J Exp Med (2001) 1.51

Tolerogenic dendritic cells generated with different immunosuppressive cytokines induce antigen-specific anergy and regulatory properties in memory CD4+ T cells. J Immunol (2010) 1.43

Exogenous IFN-gamma ex vivo shapes the alloreactive T-cell repertoire by inhibition of Th17 responses and generation of functional Foxp3+ regulatory T cells. Eur J Immunol (2008) 1.36

Mammalian target of rapamycin inhibition and alloantigen-specific regulatory T cells synergize to promote long-term graft survival in immunocompetent recipients. J Immunol (2009) 1.35

Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival. J Immunol (2000) 1.27

Expansion of antigen-specific regulatory T cells with the topical vitamin d analog calcipotriol. J Immunol (2009) 1.26

Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells. Blood (2006) 1.26

LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells. J Leukoc Biol (2008) 1.23

Interferon-gamma conditioning ex vivo generates CD25+CD62L+Foxp3+ regulatory T cells that prevent allograft rejection: potential avenues for cellular therapy. Transplantation (2008) 1.22

1,25-dihydroxyvitamin D3 is an autonomous regulator of the transcriptional changes leading to a tolerogenic dendritic cell phenotype. J Immunol (2009) 1.16

Induction of regulatory T cells and dominant tolerance by dendritic cells incapable of full activation. J Immunol (2007) 1.12

Prolongation of heart allograft survival by immature dendritic cells generated from recipient type bone marrow progenitors. Am J Transplant (2005) 1.12

Infusion of stably immature monocyte-derived dendritic cells plus CTLA4Ig modulates alloimmune reactivity in rhesus macaques. Transplantation (2007) 1.10

Rapamycin-conditioned, alloantigen-pulsed dendritic cells promote indefinite survival of vascularized skin allografts in association with T regulatory cell expansion. Transpl Immunol (2007) 1.05

Tolerogenic dendritic cells actively inhibit T cells through heme oxygenase-1 in rodents and in nonhuman primates. FASEB J (2009) 1.04

Alloreactive CD4 T cell activation in vivo: an autonomous function of the indirect pathway of alloantigen presentation. J Immunol (2003) 1.01

Induction of antigen-specific regulatory T lymphocytes by human dendritic cells expressing the glucocorticoid-induced leucine zipper. Blood (2007) 1.01

Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response. Blood (2006) 1.00

Mast cells, histamine, and IL-6 regulate the selective influx of dendritic cell subsets into an inflamed lymph node. J Immunol (2010) 0.98

Differential roles of direct and indirect allorecognition pathways in the rejection of skin and corneal transplants. Transplantation (2009) 0.95

IFN-gamma, as secreted during an alloresponse, induces differentiation of monocytes into tolerogenic dendritic cells, resulting in FoxP3+ regulatory T cell promotion. J Immunol (2009) 0.94

Gene transfer of programmed death ligand-1.Ig prolongs cardiac allograft survival. Transplantation (2006) 0.94

Induction of alloantigen-specific human T regulatory cells by vasoactive intestinal peptide. J Immunol (2009) 0.94

Generation of immunogenic dendritic cells from human embryonic stem cells without serum and feeder cells. Regen Med (2009) 0.91

Dendritic cells transduced with lentiviral vectors expressing VIP differentiate into VIP-secreting tolerogenic-like DCs. Mol Ther (2010) 0.91

Prolongation of allograft survival by 1,25-dihydroxyvitamin D3. Transplantation (1998) 0.90

Programmed death-1 signaling is essential for the skin allograft protection by alternatively activated dendritic cell infusion in mice. Transplantation (2009) 0.90

GMCSF in the absence of other cytokines sustains human dendritic cell precursors with T cell regulatory activity and capacity to differentiate into functional dendritic cells. Immunol Lett (2007) 0.90

Creation of tolerogenic human dendritic cells via intracellular CTLA4: a novel strategy with potential in clinical immunosuppression. Blood (2005) 0.89

Induction of allospecific tolerance by immature dendritic cells genetically modified to express soluble TNF receptor. J Immunol (2006) 0.89

Targeting MHC class I monomers to dendritic cells inhibits the indirect pathway of allorecognition and the production of IgG alloantibodies leading to long-term allograft survival. J Immunol (2010) 0.88

Dual effects of the alloresponse by Th1 and Th2 cells on acute and chronic rejection of allotransplants. Eur J Immunol (2009) 0.87

Generating tolerogenic dendritic cells with neuropeptides. Hum Immunol (2009) 0.87

Indoleamine 2,3-dioxygenase gene transfer prolongs cardiac allograft survival. Am J Physiol Heart Circ Physiol (2007) 0.86

Regulation of rat and human T-cell immune response by pharmacologically modified dendritic cells. Transplantation (2009) 0.86

Prolongation of composite tissue allograft survival by immature recipient dendritic cells pulsed with donor antigen and transient low-dose immunosuppression. Plast Reconstr Surg (2008) 0.85

Aspirin and the induction of tolerance by dendritic cells. Handb Exp Pharmacol (2009) 0.84

Gene transfer of a soluble IL-1 type 2 receptor-Ig fusion protein improves cardiac allograft survival in rats. Eur J Cardiothorac Surg (2006) 0.83

Dexamethasone transforms lipopolysaccharide-stimulated human blood myeloid dendritic cells into myeloid dendritic cells that prime interleukin-10 production in T cells. Immunology (2008) 0.83

The discovery of immunological tolerance: now more than just a laboratory solution. J Immunol (2010) 0.83

Induction of donor-specific T-cell hyporesponsiveness using dexamethasone-treated dendritic cells in two fully mismatched rat kidney transplantation models. Transplantation (2008) 0.82

Effective induction of immune tolerance by portal venous infusion with IL-10 gene-modified immature dendritic cells leading to prolongation of allograft survival. J Mol Med (Berl) (2004) 0.82

A tolerogenic semimature dendritic cells induce effector T-cell hyporesponsiveness by activation of antigen-specific CD4+CD25+ T regulatory cells that promotes skin allograft survival in mice. Cell Immunol (2009) 0.81

Dendritic cells secrete the immunosuppressive HLA-G molecule upon CTLA4-Ig treatment: implication in human renal transplant acceptance. J Immunol (2009) 0.81

Blockade of CD40 pathway enhances the induction of immune tolerance by immature dendritic cells genetically modified to express cytotoxic T lymphocyte antigen 4 immunoglobulin. Transplantation (2003) 0.81

Cyclosporin a Up-regulates B7-DC expression on dendritic cells in an IL-4-dependent manner in vitro, which is associated with decreased allostimulatory capacity of dendritic cells. Immunopharmacol Immunotoxicol (2008) 0.81

Induction of human CD4+ regulatory T cells by mycophenolic acid-treated dendritic cells. J Leukoc Biol (2008) 0.80

Regulating rejection with cell therapy. Nat Biotechnol (2008) 0.80

Comparative analysis of dendritic cells and anti-CD3/CD28 expanded regulatory T cells for application in transplantation. Transpl Immunol (2009) 0.79

Administration of dendritic cells modified by RNA interference prolongs cardiac allograft survival. Microsurgery (2007) 0.78

Articles by these authors

Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol (2006) 5.00

Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response. Immunity (2009) 3.32

TGF-beta induces Foxp3 + T-regulatory cells from CD4 + CD25 - precursors. Am J Transplant (2004) 3.15

Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol (2009) 2.87

Epigenetic mechanisms of regulation of Foxp3 expression. Blood (2009) 2.27

Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med (2011) 2.14

The sphingosine 1-phosphate receptor 1 causes tissue retention by inhibiting the entry of peripheral tissue T lymphocytes into afferent lymphatics. Nat Immunol (2007) 2.13

c-Maf regulates IL-10 expression during Th17 polarization. J Immunol (2009) 1.99

Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proc Natl Acad Sci U S A (2009) 1.95

CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature (2009) 1.94

Ureteral stents are associated with reduced risk of ureteral complications after kidney transplantation: a large single center experience. Transplantation (2012) 1.79

Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation. J Exp Med (2011) 1.78

Transplant glomerulopathy may occur in the absence of donor-specific antibody and C4d staining. Clin J Am Soc Nephrol (2007) 1.64

Lymph node occupancy is required for the peripheral development of alloantigen-specific Foxp3+ regulatory T cells. J Immunol (2005) 1.64

Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep (2012) 1.59

Monocytic suppressive cells mediate cardiovascular transplantation tolerance in mice. J Clin Invest (2010) 1.55

Sirolimus is associated with reduced islet engraftment and impaired beta-cell function. Diabetes (2006) 1.49

Requirements for T lymphocyte migration in explanted lymph nodes. J Immunol (2007) 1.48

Suppressor of cytokine signaling 1 inhibits IL-10-mediated immune responses. J Immunol (2003) 1.45

IL-6 plays a unique role in initiating c-Maf expression during early stage of CD4 T cell activation. J Immunol (2005) 1.42

CD4+ CD25+ CD62+ T-regulatory cell subset has optimal suppressive and proliferative potential. Am J Transplant (2004) 1.39

Identification of a distant T-bet enhancer responsive to IL-12/Stat4 and IFNgamma/Stat1 signals. Blood (2007) 1.29

Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren syndrome. Blood (2012) 1.27

Induction of mucosal tolerance in Peyer's patch-deficient, ligated small bowel loops. J Clin Invest (2005) 1.25

Committing embryonic stem cells to early endocrine pancreas in vitro. Stem Cells (2004) 1.23

FTY720 stimulates multidrug transporter- and cysteinyl leukotriene-dependent T cell chemotaxis to lymph nodes. J Clin Invest (2003) 1.18

T-bet and eomesodermin play critical roles in directing T cell differentiation to Th1 versus Th17. J Immunol (2008) 1.17

Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease. Clin Transplant (2004) 1.17

Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant (2003) 1.12

Regulatory T cell migration during an immune response. Trends Immunol (2012) 1.10

Tubular expression of KIM-1 does not predict delayed function after transplantation. J Am Soc Nephrol (2009) 1.10

Adenovirus transduction induces expression of multiple chemokines and chemokine receptors in murine beta cells and pancreatic islets. Am J Transplant (2003) 1.08

The kinetics and pattern of tracheal allograft re-epithelialization. Am J Respir Cell Mol Biol (2003) 1.07

Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome. Clin J Am Soc Nephrol (2008) 1.06

Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies. Clin J Am Soc Nephrol (2008) 1.06

Conventional dendritic cells are the critical donor APC presenting alloantigen after experimental bone marrow transplantation. Blood (2009) 1.04

Laparoscopic donor nephrectomy: intraoperative safety, immediate morbidity, and delayed complications with 500 cases. Surg Endosc (2006) 1.02

Insulin-expressing colonies developed from murine embryonic stem cell-derived progenitors. Diabetes (2007) 1.01

The chemokine binding protein M3 prevents diabetes induced by multiple low doses of streptozotocin. J Immunol (2007) 1.01

Role of donor-derived monocyte chemoattractant protein-1 in murine islet transplantation. J Am Soc Nephrol (2004) 1.01

Myeloid derived suppressor cells in transplantation. Curr Opin Immunol (2011) 0.99

Targeting lymphangiogenesis after islet transplantation prolongs islet allograft survival. Transplantation (2011) 0.99

Sphingosine 1-phosphate receptor modulators: a new class of immunosuppressants. Clin Transplant (2006) 0.99

Orthotopic tracheal transplantation in the murine model. Transplantation (2002) 0.98

FTY720-enhanced T cell homing is dependent on CCR2, CCR5, CCR7, and CXCR4: evidence for distinct chemokine compartments. J Immunol (2004) 0.98

Decreased incidence of cytomegalovirus infection in thymoglobulin-treated transplant patients with 6 months of valganciclovir prophylaxis. Am J Transplant (2004) 0.97

L-selectin-dependent lymphoid occupancy is required to induce alloantigen-specific tolerance. J Immunol (2002) 0.97

Regulatory T cell induction, migration, and function in transplantation. J Immunol (2012) 0.96

Suppression of autoimmune diabetes by viral IL-10 gene transfer. J Immunol (2002) 0.96

Lymphangiogenesis is required for pancreatic islet inflammation and diabetes. PLoS One (2011) 0.95

Islet expression of M3 uncovers a key role for chemokines in the development and recruitment of diabetogenic cells in NOD mice. Diabetes (2007) 0.95

Sphingosine 1-phosphate receptors regulate chemokine-driven transendothelial migration of lymph node but not splenic T cells. J Immunol (2005) 0.94

Functional specialization of islet dendritic cell subsets. J Immunol (2012) 0.92

Antibodies reactive to non-HLA antigens in transplant glomerulopathy. J Am Soc Nephrol (2011) 0.91

Differential expression of chemokines and chemokine receptors in murine islet allografts: the role of CCR2 and CCR5 signaling pathways. J Am Soc Nephrol (2004) 0.91

Myeloid-derived suppressor cells: natural regulators for transplant tolerance. Hum Immunol (2010) 0.91

CD4+ CD25+ regulatory T-cells inhibit the islet innate immune response and promote islet engraftment. Diabetes (2006) 0.91

Orthotopic tracheal allografts undergo reepithelialization with recipient-derived epithelium. Arch Otolaryngol Head Neck Surg (2003) 0.90

A functional role for CCR6 on proallergic T cells in the gastrointestinal tract. Gastroenterology (2009) 0.89

Therapeutic manipulation of T cell chemotaxis in transplantation. Curr Opin Immunol (2004) 0.88

Interleukin-10 From Marginal Zone Precursor B-Cell Subset Is Required for Costimulatory Blockade-Induced Transplantation Tolerance. Transplantation (2015) 0.88

Laminins affect T cell trafficking and allograft fate. J Clin Invest (2014) 0.88

Characterization of an in vitro differentiation assay for pancreatic-like cell development from murine embryonic stem cells: detailed gene expression analysis. Assay Drug Dev Technol (2011) 0.87

An update on the impact of pre-transplant transfusions and allosensitization on time to renal transplant and on allograft survival. BMC Nephrol (2013) 0.87

Clinical Trials for Immunosuppression in Transplantation; The Case for Reform and Change in Direction. Transplantation (2017) 0.87

Differential chemokine and chemokine receptor gene induction by ischemia, alloantigen, and gene transfer in cardiac grafts. Am J Transplant (2003) 0.86

Leukotrienes, sphingolipids, and leukocyte trafficking. J Immunol (2003) 0.86

Intravenous immunoglobulin and thymoglobulin induction treatment in immunologically high-risk kidney transplant recipients. Transplantation (2005) 0.85

Islet-expressed TLR2 and TLR4 sense injury and mediate early graft failure after transplantation. Eur J Immunol (2010) 0.85

Intravenous immunoglobulin and thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell crossmatch-positive patients. Transplantation (2003) 0.85

Plasmacytoid dendritic cells in tolerance. Methods Mol Biol (2011) 0.84

Tolerance and lymphoid organ structure and function. Front Immunol (2011) 0.83

Intravenous immunoglobulin induction treatment in flow cytometry cross-match-positive kidney transplant recipients. Hum Immunol (2005) 0.83

Live Donor Renal Transplant With Simultaneous Bilateral Nephrectomy for Autosomal Dominant Polycystic Kidney Disease Is Feasible and Satisfactory at Long-term Follow-up. Transplantation (2016) 0.83

Stat4 is critical for the balance between Th17 cells and regulatory T cells in colitis. J Immunol (2011) 0.83

Effect of high-dose intravenous immunoglobulin on anti-HLA antibodies in sensitized kidney transplant candidates. Clin Transplant (2012) 0.82

Transduction of pancreatic islets with pseudotyped adeno-associated virus: effect of viral capsid and genome conversion. Transplantation (2005) 0.81

Safety of using hepatitis B virus core antibody or surface antigen-positive donors in kidney or pancreas transplantation. Clin Transplant (2005) 0.81

Vascular endothelial growth factor c/vascular endothelial growth factor receptor 3 signaling regulates chemokine gradients and lymphocyte migration from tissues to lymphatics. Transplantation (2015) 0.81

NK cells are required for costimulatory blockade induced tolerance to vascularized allografts. Transplantation (2012) 0.81

Differential outcomes in 3 types of acute antibody-mediated rejection. Clin Transplant (2009) 0.80

Diabetes cure--is the glass half full? N Engl J Med (2006) 0.80

Viral IL-10 gene transfer inhibits the expression of multiple chemokine and chemokine receptor genes induced by inflammatory or adaptive immune stimuli. Am J Transplant (2003) 0.80

High dose intravenous immunoglobulin treatment: mechanisms of action. Liver Transpl (2005) 0.79

De novo autoimmunity after organ transplantation: targets and possible pathways. Hum Immunol (2008) 0.79